AC
SLXNW

Aristeia Capital’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Aristeia Capital’s Portfolio SLXNW Stock Details SLXNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.05K Hold
236,546
– – ﹤0.01% 686
2025
Q4 		$6.29K Hold
236,546
– – ﹤0.01% 595
2025
Q3 		$8.34K Hold
236,546
– – ﹤0.01% 518
2025
Q2 		$9.78K Hold
236,546
– – ﹤0.01% 463
2025
Q1 		$16.5K Sell
236,546
-5,628
-2% -$343 ﹤0.01% 391
2024
Q4 		$9.9K Hold
242,174
– – ﹤0.01% 360
2024
Q3 		$12.3K Buy
+242,174
New +$14K ﹤0.01% 319

Other funds holding SLXNW

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
SBLIC
Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.39% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Aristeia Capital's SLXNW Position: Q1 2026 in Review

Aristeia Capital held its Silexion Therapeutics Warrant (SLXNW) position steady in Q1 2026 at 236,546 shares worth $5.05K. The position accounts for ﹤0.01% of the portfolio, ranked #686.

Aristeia Capital first reported a position in SLXNW in Q3 2024 and has held it in 7 quarters since. The position peaked at $16.5K in Q1 2025. 19 funds tracked by Wall St. Rank hold SLXNW as of Q1 2026.

  • Aristeia Capital held 236,546 shares of Silexion Therapeutics Warrant worth $5.05K as of Q1 2026.
  • Aristeia Capital left its Silexion Therapeutics Warrant share count unchanged in Q1 2026.
  • Silexion Therapeutics Warrant made up ﹤0.01% of Aristeia Capital's portfolio in Q1 2026, its #686 holding.
  • Aristeia Capital first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 7 quarters since.
  • Aristeia Capital's Silexion Therapeutics Warrant position peaked at $16.5K in Q1 2025.
  • 19 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q1 2026.

Based on Aristeia Capital's 13F filing for Q1 2026, filed 15 May 2026.